Skip to main content

Beta Bionics, Inc.

corporate_fare Company Profile

Beta Bionics, Inc.

BBNX·NASDAQ·Industrial Applications And Services·CIK 0001674632

We are a commercial-stage medical device company focused on designing, developing, and selling innovative solutions to improve the health and quality of life for people with diabetes who require insulin. We achieve this by using advanced adaptive closed-loop algorithms to simplify and improve their disease treatment. Our product, the iLet Bionic Pancreas (iLet), received clearance from the U.S. Food and Drug Administration (FDA) for treating Type 1 diabetes in adults and children aged six years and older. The iLet was commercially launched in May 2023 in the United States. As of December 31, 2025, our installed base has grown to 35,011 iLets. Diabetes is a serious, chronic condition characterized by high blood glucose levels due to the body's inability to produce or effectively use insulin. People with diabetes must follow a strict daily insulin regimen to avoid serious complications. Type 1 diabetes (T1D) is an autoimmune disorder, often developing in childhood, where the immune system destroys insulin-producing cells. Approximately 1.9 million people in the United States have T1D and require daily insulin. Type 2 diabetes (T2D) is a metabolic disorder, typically developing in adulthood, where the body becomes insulin resistant, requiring increased insulin production or replacement.

Beta Bionics, Inc. (NASDAQ:BBNX) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 27 items for BBNX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-27, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for BBNX spans 10-Q, 8-K, 424B5, FWP.

Recent high-impact activity:

  • Beta Bionics Q3 Sales Up 30% to $35.5M; Loss Widens to $24.4M, Cash at $373.6M
  • Beta Bionics Q3 Sales Up 30% to $35.5M; Guidance Raised, 3D Intelligence 510(k) Withdrawn
  • Beta Bionics Q3 Sales Up 30% but Losses Widen; 3D Intelligence 510(k) Withdrawn
  • Beta Bionics Plunges 37% on Safety Disclosure; Securities Fraud Class Action Filed
  • Beta Bionics Partners with Senseonics to Integrate iLet and mint with Eversense 365

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$100.25M
Net Income
-$73.2M
Diluted EPS
-$1.81
Op. Cash Flow
-$50.92M
Free Cash Flow
-$56.22M
Gross Profit
$55.54M
Operating Income
-$71.68M
Cash & Equivalents
$31.58M
Debt / Equity
0.00×
Net Margin
-73.0%
Shares Outstanding
44.36M sh
Source: 10-K · filed 2026-02-24 · accession 0001193125-26-067065

Short Interest & Short Volume

3.94 days to cover

FINRA reported short interest of 4,980,771 shares in BBNX as of the October 30, 2026 settlement, a 28.0% decrease from the prior period — about 3.9 days to cover at its recent average daily volume. On November 20, 2026, 54.9% of BBNX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)4,980,771 shares as of October 30, 2026
Change vs prior period▼ 28.0%
Days to cover3.94 at avg daily volume of 1,265,283
Daily short volume (FINRA facilities)54.9% of 292,068 shares on November 20, 2026
5-day average short volume47.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for BBNX, detected from its recent SEC filings · based on capital-structure filings through 2026-09-16.

1 recent capital raise

Offering Upsized to $150M · Pre-Funded Warrants Added

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with B →
$13.36
52-week range · as of 2026-10-27 $8.8 – $32.71
Market cap
$726.34M
Volume
960.3K (0.8× avg)
3-mo avg 1.2M
Live data · 2026-11-21 21:16 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BBNX - Latest Insights

BBNX
Oct 27, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $18.92
Real-time Price: $13.36 info
Change: -$5.56 (-29%) info
Market Cap: $726.344M info
BBNX
Oct 27, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $20.89
Real-time Price: $13.36 info
Change: -$7.53 (-36%) info
Market Cap: $726.344M info
BBNX
Oct 27, 2026, 4:02 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $21.01
Real-time Price: $13.36 info
Change: -$7.65 (-36%) info
Market Cap: $726.344M info
BBNX
Oct 06, 2026, 5:36 AM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $18.95
Real-time Price: $13.36 info
Change: -$5.59 (-29%) info
Market Cap: $726.344M info
BBNX
Sep 22, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $22.19
Real-time Price: $13.36 info
Change: -$8.83 (-40%) info
Market Cap: $726.344M info
BBNX
Sep 17, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $21.19
Real-time Price: $13.36 info
Change: -$7.83 (-37%) info
Market Cap: $726.344M info
BBNX
Sep 16, 2026, 6:24 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.15
Real-time Price: $13.36 info
Change: -$8.79 (-40%) info
Market Cap: $726.344M info
BBNX
Sep 16, 2026, 6:21 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $22.15
Real-time Price: $13.36 info
Change: -$8.79 (-40%) info
Market Cap: $726.344M info
BBNX
Sep 15, 2026, 11:57 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $18.11
Real-time Price: $13.36 info
Change: -$4.75 (-26%) info
Market Cap: $726.344M info
BBNX
Sep 15, 2026, 8:15 PM EDT
Filing Type: FWP
Importance Score:
7
Price at Filing: $18.15
Real-time Price: $13.36 info
Change: -$4.79 (-26%) info
Market Cap: $726.344M info
BBNX
Sep 15, 2026, 8:13 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $18.15
Real-time Price: $13.36 info
Change: -$4.79 (-26%) info
Market Cap: $726.344M info
BBNX
Sep 15, 2026, 4:58 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $18.47
Real-time Price: $13.36 info
Change: -$5.11 (-28%) info
Market Cap: $726.344M info
BBNX
Sep 15, 2026, 4:13 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $17.70
Real-time Price: $13.36 info
Change: -$4.34 (-25%) info
Market Cap: $726.344M info
BBNX
Sep 14, 2026, 7:30 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $15.98
Real-time Price: $13.36 info
Change: -$2.62 (-16%) info
Market Cap: $726.344M info
BBNX
Jul 29, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $15.61
Real-time Price: $13.36 info
Change: -$2.25 (-14%) info
Market Cap: $726.344M info
BBNX
Jul 29, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $15.45
Real-time Price: $13.36 info
Change: -$2.09 (-14%) info
Market Cap: $726.344M info
BBNX
Jul 29, 2026, 4:02 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $15.61
Real-time Price: $13.36 info
Change: -$2.25 (-14%) info
Market Cap: $726.344M info
BBNX
Jun 08, 2026, 8:16 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $13.78
Real-time Price: $13.36 info
Change: -$0.420 (-3%) info
Market Cap: $726.344M info
BBNX
May 21, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.80
Real-time Price: $13.36 info
Change: +$2.56 (+24%) info
Market Cap: $726.344M info
BBNX
Apr 21, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $12.01
Real-time Price: $13.36 info
Change: +$1.35 (+11%) info
Market Cap: $726.344M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets